Does INFLIXIMAB-DYYB Cause Product availability issue? 68 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 68 reports of Product availability issue have been filed in association with INFLIXIMAB-DYYB (ZYMFENTRA). This represents 0.3% of all adverse event reports for INFLIXIMAB-DYYB.
68
Reports of Product availability issue with INFLIXIMAB-DYYB
0.3%
of all INFLIXIMAB-DYYB reports
0
Deaths
10
Hospitalizations
How Dangerous Is Product availability issue From INFLIXIMAB-DYYB?
Of the 68 reports, 10 (14.7%) required hospitalization, and 1 (1.5%) were considered life-threatening.
Is Product availability issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB-DYYB. However, 68 reports have been filed with the FAERS database.
What Other Side Effects Does INFLIXIMAB-DYYB Cause?
Off label use (14,256)
Condition aggravated (10,275)
Intentional product use issue (7,549)
Inappropriate schedule of product administration (5,977)
Arthralgia (4,615)
Drug ineffective (3,112)
Fatigue (3,111)
Weight increased (2,848)
Malaise (2,766)
Weight decreased (2,703)
What Other Drugs Cause Product availability issue?
RUXOLITINIB (2,142)
LISDEXAMFETAMINE DIMESYLATE (1,530)
CERTOLIZUMAB PEGOL (1,381)
VEDOLIZUMAB (636)
AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (610)
METHYLPHENIDATE (444)
SECUKINUMAB (399)
BIMEKIZUMAB-BKZX (364)
LACOSAMIDE (359)
BRIVARACETAM (324)
Which INFLIXIMAB-DYYB Alternatives Have Lower Product availability issue Risk?
INFLIXIMAB-DYYB vs INFLIXIMAB-QBTX
INFLIXIMAB-DYYB vs INFLIXIMAB, RECOMBINANT
INFLIXIMAB-DYYB vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN
INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE
INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B